272 articles with Ablynx
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
Ablynx Completes Patient Recruitment in the Phase IIb Respire Study of Its Inhaled Anti-RSV Nanobody ALX-0171
Ablynx announced that it has successfully completed patient recruitment in the Phase IIb RESPIRE dose-ranging efficacy study of ALX- 0171, the Company’s novel inhaled drug candidate to treat respiratory syncytial virus (RSV) infections.
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
Dr Bo Jesper Hansen has decided to resign from the Board of Directors with immediate effect for personal reasons.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations.
As a result of these transactions, Ablynx now has a share capital of €140,320,046.59 represented by a total number of 75,065,990 shares, conferring a total number of 75,065,990 voting rights.
Ablynx: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") – Jan. 18, 2018
The notifications contain the following information:
Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law") – Jan. 16, 2018
Van Herk Investments B.V. notified Ablynx that it has crossed the 10% threshold on 12 January 2018 and now holds 7,629,229 voting securites of Ablynx.
Ablynx: Publication In Accordance With Article 14 of The Belgian Law Of 2 May 2007 Regarding The Publication of Major Shareholdings (The "Transparency Law") - Jan. 10, 2018
The company received a notification of shareholdings from Consonance CapMan GP LLC on 5 January 2018.
The offers underline Novo Nordisk's interest in expanding beyond diabetes and into the rare diseases market.
Will this new buy be enough for Celgene investors?
Ablynx today announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board with immediate effect.
Ablynx today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific Standard Time (06:30 p.m. Central European Time).
The waiver will take effect on 29 December 2017 and the securities may be sold on or after such date.
Ablynx today announced that the single and multiple dose Phase I study demonstrated comparable PK of caplacizumab in Japanese and Caucasian subjects.